Ligand Pharmaceuticals (LGND) Current Deferred Revenue (2010 - 2025)

Ligand Pharmaceuticals (LGND) has 14 years of Current Deferred Revenue data on file, last reported at $111000.0 in Q2 2025.

• For the quarter ending Q2 2025, Current Deferred Revenue fell 90.72% year-over-year to $111000.0; the trailing twelve-month figure through Jun 2025 stood at $111000.0 (down 90.72% YoY), and the FY2024 full-year result was $1.3 million, up 4.58% from the prior year.
• Current Deferred Revenue rose to $111000.0 in Q2 2025, from $101000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $25.1 million in Q1 2021 to a low of $101000.0 in Q1 2025.
• A 5-year average of $5.8 million and a median of $1.2 million in 2023 frame the typical range for Current Deferred Revenue.
• Peak annual rise in Current Deferred Revenue reached 476.64% in 2021, while the deepest fall reached 97.78% in 2021.
• Tracing LGND's Current Deferred Revenue over 5 years: stood at $654000.0 in 2021, then slumped by 45.72% to $355000.0 in 2022, then jumped by 244.23% to $1.2 million in 2023, then rose by 4.58% to $1.3 million in 2024, then tumbled by 91.31% to $111000.0 in 2025.
• Business Quant data shows LGND's Current Deferred Revenue at $111000.0 in Q2 2025, $101000.0 in Q1 2025, and $1.3 million in Q4 2024.